Company Profile

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California.

Corporate Speaker

David Stamler alterity therapeutics

David Stamler, M.D.

CEO

David Stamler, M.D. was appointed Chief Executive Officer in January 2021 and previously served as our Chief Medical Officer and Senior Vice President, Clinical Development since May of 2017.  Before joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals and was the Chief Medical Officer of Auspex prior to the acquisition.

Previously, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., a publicly traded biopharmaceutical company, Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc., a private pharmaceutical company. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories, a publicly traded global pharmaceuticals and healthcare products company, where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.

Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

Company Website

Stock Info:

NASDAQ: ATHE, ASX: ATH

Agenda

Agenda